Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Receivables - Net: 2017-2024

Historic Receivables - Net for Aclaris Therapeutics (ACRS) over the last 8 years, with Dec 2024 value amounting to $318,000.

  • Aclaris Therapeutics' Receivables - Net fell 72.29% to $194,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $194,000, marking a year-over-year decrease of 72.29%. This contributed to the annual value of $318,000 for FY2024, which is 6.71% up from last year.
  • According to the latest figures from FY2024, Aclaris Therapeutics' Receivables - Net is $318,000, which was up 6.71% from $298,000 recorded in FY2023.
  • Aclaris Therapeutics' Receivables - Net's 5-year high stood at $772,000 during FY2020, with a 5-year trough of $298,000 in FY2023.
  • Over the past 3 years, Aclaris Therapeutics' median Receivables - Net value was $318,000 (recorded in 2024), while the average stood at $366,667.
  • Its Receivables - Net has fluctuated over the past 5 years, first climbed by 9.66% in 2020, then tumbled by 38.43% in 2023.
  • Yearly analysis of 5 years shows Aclaris Therapeutics' Receivables - Net stood at $772,000 in 2020, then declined by 19.30% to $623,000 in 2021, then fell by 22.31% to $484,000 in 2022, then slumped by 38.43% to $298,000 in 2023, then rose by 6.71% to $318,000 in 2024.